-
Article
Open AccessAssociation of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer
Antibiotic exposure during immunotherapy (IO) has been shown to negatively affect clinical outcomes in various cancer types. The aim of this study was to evaluate whether antibiotic exposure in patients with h...
-
Article
Open AccessObesity-associated changes in molecular biology of primary breast cancer
Obesity is associated with an increased risk of develo** breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study investigates how the bi...
-
Article
Open AccessDevelopment and testing of a polygenic risk score for breast cancer aggressiveness
Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using ...
-
Article
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study
Disseminated tumor cells (DTCs) expressing epithelial markers in the bone marrow are associated with recurrence and death, but little is known about risk factors predicting their occurrence. We detected EPCAM+...
-
Article
Open AccessThe incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
When molecular testing classifies breast tumors as low risk but clinical risk is high, the optimal management strategy is unknown. One group of patients who may be more likely to have such discordant risk are ...
-
Article
Open AccessRAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
HER2 is a predictive biomarker for HER2-targeted therapeutics. For antibody–drug conjugates (ADCs; e.g., trastuzumab emtansine (T-DM1)), HER2 is utilized as a transport gate for cytotoxic agents into the cell....
-
Article
The WISDOM study: a new approach to screening can and should be tested
-
Article
Open AccessCirculating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
We investigated whether serial measurements of circulating tumor DNA (ctDNA) and functional tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve prediction of pathologic complete r...
-
Article
Open AccessToward develo** a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments
Information regarding response to past treatments may provide clues concerning the classes of drugs most or least likely to work for a particular metastatic or neoadjuvant early stage breast cancer patient. Ho...
-
Article
Open AccessMechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
The AKT inhibitor MK2206 (M) was evaluated in I-SPY 2 and graduated in the HER2+, HR−, and HR− HER2+ signatures. We hypothesized that AKT signaling axis proteins/genes may specifically predict response to M an...
-
Article
Open AccessControlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial
Gene expression data obtained in large studies hold great promises for discovering disease signatures or subtypes through data analysis. It is also prone to technical variation, whose removal is essential to a...
-
Article
A response to “Personalised medicine and population health: breast and ovarian cancer”
-
Article
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences
In the Methods section of this Article, ‘greater than’ should have been ‘less than’ in the sentence ‘Putative regions of clustered rearrangements were identified as having an average inter-rearrangement distan...
-
Article
Open AccessGenomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer
Detection of disseminated tumor cells (DTCs) in bone marrow is an established negative prognostic factor. We isolated small pools of (~20) EPCAM-positive DTCs from early breast cancer patients for genomic prof...
-
Article
Open AccessHeterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that ...
-
Article
Open AccessDNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. H...
-
Article
Open AccessThe BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
Patients with BRCA1-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed to distinguish between BRCA1-like and non-BRCA1-like ...
-
Article
Open AccessMulti-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
Many women with an elevated risk of hereditary breast and ovarian cancer have previously tested negative for pathogenic mutations in BRCA1 and BRCA2. Among them, a subset has hereditary susceptibility to cancer a...
-
Article
Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer
There is a growing body of literature demonstrating that immune-related expression signatures predict breast cancer prognosis and chemo-/targeted-therapy responsiveness. However, it is unclear whether these si...
-
Article
Open AccessPrognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups
The value of KI67 in breast cancer prognostication has been questioned due to concerns on the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we investi...
